Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · ZIMLAB

ZIMLAB

HealthcarePharmaceuticals & Biotechnology₹742 cr market cap
₹152.54 ▲ +12.6% today As of 19 Nov 2026
52-week low ₹60.2652-week high ₹152.63

-11.2% from the 52-week high · +124.8% above the low

Zim Laboratories Ltd. is a pharmaceutical company. The company is headquartered in Nagpur, Maharashtra and currently employs 525 full-time employees. The company went IPO on 2018-06-08. The firm develops, manufactures and supplies oral, solid differentiated generic pharmaceutical formulations and pre-formulation intermediaries (PFI) in various therapeutic segments. Its delivery solutions cover product conceptualization product development, filing for registration, manufacture, and supply of various pharmaceutical formulations. The company is developing products in various therapeutic segments like, central nervous system, anti-biotic and anti-infective, gastrointestinal, cardiovascular, analgesic/pain management, urology and vitamins, minerals, and dietary supplements. Its technological capabilities include drug release modification, solubility and stability enhancement, taste masking and dosage form transformation. Its product offerings include finished formulations and pre-formulations intermediates, which include granules, pellets, taste-masked powders, dry suspensions, tablets, capsules, and oral thin films.

The short version. ZIMLAB reported revenue of ₹105 crore for Sep 2026, up 18.0% from a year earlier. Return on equity was 2.0% in Mar 2026. Promoter holding was 30.3% in Sep 2026, down 2.96 points over 8 quarters.

1 · The price

How has the stock traded?

ZIMLAB trades 11.2% below its 52-week high and 124.8% above its 52-week low.

Change over period: —

1M-2.0%
3M+14.8%
6M+36.7%
1Y+82.2%

2 · The business

Is it growing?

Sales, year on year+18.0%

Sep 2026 revenue of ₹105 cr.

Net margin-1.9%

1.4 pts lower than a year earlier.

3-year growth-38.0% profit

Revenue compounded at -1.6% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue10594105109897210996
Net profit-2-4440-254
Net margin %-1.9-4.33.64.0-0.5-2.64.54.2
EPS (₹)-0.38-0.750.70.9-0.09-0.381.00.82

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue374379367399333307278335
Net profit6121724157315
Net margin %1.63.24.76.14.42.21.24.6
EPS (₹)1.092.53.545.012.991.410.683.17

3 · The quality

How well does it turn capital into profit?

Return on equity was 2.0% in Mar 2026; debt to equity is 0.42.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %2.04.87.212.2
Return on capital %6.19.610.617.7
EBITDA margin %10.712.912.514.4
Net margin %1.53.24.66.0

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR-1.6%4.5%
Profit CAGR-38.0%-3.2%
Debt to equity0.42
Interest cover1.6x
Current ratio1.45

4 · The owners

Who holds it, and are they adding?

Promoter holding30.3%

Down 2.96 pts over 8 quarters.

Foreign institutions0.17%

Down 0.04 pts over 8 quarters.

Domestic institutions1.19%

Up 0.95 pts over 8 quarters.

Mutual fund schemes1

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter33.2633.2633.2633.2633.2630.3530.3630.3-2.96
FII0.210.010.0300.0200.030.17-0.04
DII0.240.240.240.240.20.071.331.19+0.95
Public66.2866.4966.4666.5166.5269.5868.2868.34+2.06

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for ZIMLAB are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about ZIMLAB

What is the ZIMLAB share price?

ZIMLAB (ZIMLAB) last closed at ₹152.54, up 12.6% on the day. Its 52-week range is ₹60.26 to ₹152.63.

What is the market cap of ZIMLAB?

ZIMLAB has a market capitalisation of about ₹742 crore.

How are ZIMLAB's latest results?

ZIMLAB reported revenue of ₹105 crore for Sep 2026, up 18.0% from a year earlier. Return on equity was 2.0% in Mar 2026. Promoter holding was 30.3% in Sep 2026, down 2.96 points over 8 quarters.

Who owns ZIMLAB?

As of Sep 2026, shareholding was: Promoter 30.3%, FII 0.17%, DII 1.19%, Public 68.34%.

How many mutual funds hold ZIMLAB?

1 mutual fund schemes held ZIMLAB in October 2026. That compares with 1 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 22 Dec 2022 · Bonus issue 2:1
  • 19 Sep 2019 · Dividend - Rs. 0.5
  • 04 Oct 2018 · Bonus issue 1:1
  • 03 Sep 2018 · Final Dividend - Rs. 1

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.